They must triple soon
Wheeler the Wise has spoken
I think this POS peaked. I sold at $14.11 after seeing Belviq gaining traction per Osborne, and the management shakeup. I may buy back in in the $8-$10 range if it looks like FMC can turn this POS around.
Q3 CC will be another heavy unavoidable loss. VVUS is a falling knife. Ironically, the best thing VVUS has going for it is ARNA.
By end of year, they can triple the sales, Qysmai scripts to 30,000 per week and VVUS becomes profitable.
Sentiment: Strong Buy
That is a poor wager.
vivus scripts are already around 150k a month......well the generic components at least. Why should that change? Doctors arent stupid.
More than that to get revenue to pay for all the costs, REMS, debt, etc.